Novartis now expects its core operating profit to grow in the mid-to-high single digits, after second-quarter results beat analysts’ expectations, driven by revenue from breakthrough treatments.
Novartis now expects its core operating profit to grow in the mid-to-high single digits, after second-quarter results beat analysts’ expectations, driven by revenue from breakthrough treatments.
